No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Care Facilities
Mediclin AG is a German healthcare enterprise primarily engaged in managing hospitals across the nation. Its operations are categorized into three main segments: Post-Acute, Acute, and various other related activities. The company offers a comprehensive range of medical specializations, encompassing fields such as neurology, psychosomatics, orthopaedics, internal medicine, cardiology, oncology, geriatrics, psychiatry, and surgical interventions, in addition to general nursing care. Furthermore, Mediclin provides specialized services like ear, nose, and throat (ENT) treatment and acute outpatient care. As of December 31, 2021, its extensive network comprised 34 clinics, 7 nursing care facilities, and 11 medical care centres. This infrastructure collectively provided a significant capacity of 7,831 beds and 482 nursing places, distributed across eleven of Germany's federal states. The company's corporate headquarters are situated in Offenburg, Germany.
www.mediclin.deNo one on the platform currently holds MED.DE.
No tracked institution reports a position in MED.DE as of their last filing.
No one on the platform has traded MED.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.0% | — | — | — | ||
| Rev. Growth % | 4.8% | 3.5% | ||||
| Profit Margin % | 3.2% | 1.3% | 1.1% | |||
| Free Cash Flow Margin % | 6.6% | 5.6% | 4.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $824M | +6.1% | $0.79 | $0.79–$0.79 | — | 1 |
| 2027 | $848M | +3.0% | $0.87 | $0.87–$0.87 | — | 1 |
| 2028 | $874M | +3.0% | $0.97 | $0.97–$0.97 | — | 1 |
| 2029 | $900M | +3.0% | $1.04 | $1.04–$1.04 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $46M |
| — |
| HPHA.DEHeidelberg Pharma AG | $2.51 | +4.58% | $117M | — |
| LIK.DELIMES Schlosskliniken AG | $530.00 | +0.00% | $158M | — |
Source: Financial Modeling Prep · peers by sector/industry